A multiple-dose, double-blind, randomized, four-week, three-treatment, parallel study in which 66 healthy adult subjects will receive 6 capsules/d, administered as a dose of 1.3 g/d eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA) in fish oil ethyl ester (EE), or fish oil triglyceride (TG) or krill oil for a total of 4 weeks. The objective of the study is to compare the oral bioavailability of EPA+DHA in total plasma across the three formulations at the end of the 4 week study.

Inclusion Criteria:

• Healthy,
• adult female who is neither pregnant nor breastfeeding, or
• a healthy, adult male
• with a body mass index (BMI) between 18 and 30 kg/m2 (inclusive), and
• with a minimum weight of 50 kg (110 lbs).

Exclusion Criteria:

• history or presence of diabetes, high triglycerides (≥240 mg/dL), or high cholesterol (≥240 mg/dL);
• clinically significant abnormal finding on the physical exam, medical history, vital signs, or clinical laboratory results at screening;
• history or presence of allergic response to omega-3-fatty acids or sensitivity or allergy to fish or shellfish;
• history of coagulation disorder or current anticoagulation therapy;
• has used any nutritional supplements, omega-3 supplements, fish oil, chia, krill oil, flaxseed or foods supplemented with omega-3s within 3 months prior to the first dose of study medication;
• has used any prescription medication, except hormonal contraceptive or hormonal replacement therapy, within 14 days prior to the first dose of study medication.